CBD showed limited benefit for rare KCNT1 epilepsy in 3 infants, with one showing reduced seizure intensity
In 3 infants with KCNT1-related epilepsy of infancy with migrating focal seizures, pharmaceutical CBD produced no overall seizure frequency reduction, though one patient showed notably reduced seizure intensity and possible developmental gains.
Quick Facts
What This Study Found
Three patients with EIMFS secondary to KCNT1 mutations received pharmaceutical-grade CBD. Two patients showed no benefit and discontinued treatment. One patient showed no overall seizure frequency reduction but had notable reduction in seizure intensity and possible developmental progression. The results contrast with CBD efficacy in Dravet and Lennox-Gastaut syndromes.
Key Numbers
3 patients with KCNT1 mutations; 2 showed no benefit; 1 showed reduced seizure intensity but not frequency; the responder also had possible developmental progression.
How They Did This
Open-label, prospective interventional study of 3 patients with EIMFS caused by KCNT1 mutations treated with pharmaceutical-grade CBD as adjunctive therapy.
Why This Research Matters
EIMFS is a devastating rare epilepsy with almost no treatment options. While results were mostly negative, the one partial responder suggests that seizure intensity (not just frequency) may be a meaningful outcome measure for CBD.
The Bigger Picture
CBD mechanism likely differs by epilepsy subtype. The lack of response in KCNT1-related epilepsy (a potassium channelopathy) contrasts with Dravet syndrome (sodium channel), suggesting CBD anti-seizure effects may be channel-specific.
What This Study Doesn't Tell Us
Only 3 patients (no statistical power); open-label; no control group; mixed results; EIMFS is extremely rare, making large studies difficult; seizure intensity assessment is subjective.
Questions This Raises
- ?Does the seizure mechanism (sodium vs potassium channel) determine CBD responsiveness?
- ?Should seizure intensity be a primary outcome measure for refractory epilepsy trials?
Trust & Context
- Key Stat:
- 1 of 3 patients showed reduced seizure intensity with CBD
- Evidence Grade:
- Preliminary: only 3 patients in an uncontrolled open-label study, though the rare disease context limits feasibility of larger trials.
- Study Age:
- Published 2020.
- Original Title:
- Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study.
- Published In:
- European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 25, 77-81 (2020)
- Authors:
- Poisson, Kelsey, Wong, Matthew(2), Lee, Chon, Cilio, Maria Roberta
- Database ID:
- RTHC-02783
Evidence Hierarchy
A small preliminary study to test whether a larger study is feasible.
What do these levels mean? →Frequently Asked Questions
Does CBD work for all types of epilepsy?
This study suggests not. CBD showed limited benefit for KCNT1-related epilepsy, contrasting with its proven efficacy in Dravet and Lennox-Gastaut syndromes. The underlying genetic mechanism may determine whether CBD helps.
What is EIMFS?
Epilepsy of Infancy with Migrating Focal Seizures is a rare, severe epilepsy that begins within 6 months of life, most commonly caused by KCNT1 potassium channel mutations. Seizures migrate across brain regions and resist standard medications.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-02783APA
Poisson, Kelsey; Wong, Matthew; Lee, Chon; Cilio, Maria Roberta. (2020). Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study.. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 25, 77-81. https://doi.org/10.1016/j.ejpn.2019.12.024
MLA
Poisson, Kelsey, et al. "Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study.." European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2020. https://doi.org/10.1016/j.ejpn.2019.12.024
RethinkTHC
RethinkTHC Research Database. "Response to cannabidiol in epilepsy of infancy with migratin..." RTHC-02783. Retrieved from https://rethinkthc.com/research/poisson-2020-response-to-cannabidiol-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.